Financing ·
Glucotrack, Inc. entered into a Settlement and Release Agreement on September 4, 2026, resolving disputes regarding…
GCTKGlucotrack, Inc.
Glucotrack, Inc. entered into a Settlement and Release Agreement on September 4, 2026, resolving disputes regarding approximately $10.9 million in indebtedness owed by Apimeds Pharmaceuticals US, Inc. to Alto Opportunity Master Fund, SPC – Segregated Master Portfolio B. Under the agreement, Glucotrack is jointly obligated to pay an initial $2.0 million cash payment and issue a convertible promissory note for an additional $2.0 million. The note bears 5% annual interest and requires four quarterly principal installments of $500,000 beginning November 30, 2026. Alto may elect to convert the outstanding principal into common stock at $2.98 per share. Glucotrack operates in the healthcare sector, developing medical devices for diabetes management.